Pathway implications of aberrant global methylation in adrenocortical cancer

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Legendre, Christophe R ^a   Demeure, Michael J ^a   Whitsett, Timothy G ^a   Gooden, Gerald C ^a   Bussey, Kimberly J ^a,b   Jung, Sungwon ^c   Waibhav, Tembe ^a   Kim, Seungchan ^a   Salhia, Bodour ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b NantOmics   (United States)

^c Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MARCKS PROTEIN; PROTEIN P53; SOMATOMEDIN; WNT PROTEIN; DNA; TUMOR PROTEIN;

ADRENAL CORTEX CARCINOMA; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE SILENCING; GENOMICS; HUMAN; HUMAN TISSUE; MOLECULAR PATHOLOGY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ADRENAL CORTEX TUMOR; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; SIGNAL TRANSDUCTION;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84962484139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150629     Document Type: Article

References (36)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. The Journal of clinical endocrinology and metabolism. 2009;94(6):1853-78. doi: 10.1210/jc.2008-2291 PMID: 19494161.
2. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World journal of surgery. 2006;30(5):872-8. doi: 10.1007/s00268-005-0329-x PMID: 16680602.
3. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clinical endocrinology. 2004;60(3):273-87. PMID: 15008991.
4. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130-6. doi: 10.1002/cncr.23886 PMID: 18973179.
5. Demeure MJ, Somberg LB. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. Surgical oncology clinics of North America. 1998;7(4):791-805. PMID: 9735134.
6. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. The New England journal of medicine. 2012;366(23):2189-97. doi: 10.1056/NEJMoa1200966 PMID: 22551107.
7. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nature genetics. 2014. doi: 10.1038/ng.2953 PMID: 24747642.
8. Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S, et al. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. 2013;154(6):1405-16; discussion 16. doi: 10.1016/j.surg.2013.06.058 PMID: 24238056.
9. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. The Journal of clinical endocrinology and metabolism. 1994;78(3):790-4. doi: 10.1210/jcem.78.3.8126158 PMID: 8126158.
10. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-related cancer. 2007;14(1):13-28. doi: 10.1677/erc.1.01130 PMID: 17395972.
11. Demeure MJ, Bussey KJ, Kirschner LS. Targeted therapies for adrenocortical carcinoma: IGF and beyond. Hormones & cancer. 2011;2(6):385-92. doi: 10.1007/s12672-011-0090-6 PMID: 22170383.
12. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer research. 2005;65(17):7622-7. doi: 10.1158/0008-5472. CAN-05-0593 PMID: 16140927.
13. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes, chromosomes & cancer. 2012;51(10):949-60. doi: 10.1002/gcc.21978 PMID: 22733721.
14. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. The Journal of clinical endocrinology and metabolism. 2012;97(6):E1004-13. doi: 10.1210/jc.2011-3298 PMID: 22472567; PubMed Central PMCID: PMC3387424.
15. Barreau O, Assie G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. The Journal of clinical endocrinology and metabolism. 2013;98(1):E174-84. doi: 10.1210/jc.2012-2993 PMID: 23093492.
16. Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J, et al. DNA methylation in multiple myeloma is weakly associated with gene transcription. PloS one. 2012;7(12):e52626. doi: 10.1371/journal.pone. 0052626 PMID: 23285118; PubMed Central PMCID: PMC3527579.
17. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nature genetics. 2006;38(5):500-1. doi: 10.1038/ng0506-500 PMID: 16642009.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64. doi: 10.1093/biostatistics/4.2.249 PMID: 12925520.
19. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-27. doi: 10.1093/biostatistics/kxj037 PMID: 16632515.
20. Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB, et al. IMA: an R package for highthroughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics. 2012;28(5):729-30. doi: 10.1093/bioinformatics/bts013 PMID: 22253290; PubMed Central PMCID: PMC3289916.
21. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15(2):668-76. doi: 10.1158/1078-0432. CCR-08-1067 PMID: 19147773; PubMed Central PMCID: PMC2629378.
22. Cedar H, Bergman Y. Programming of DNA methylation patterns. Annual review of biochemistry. 2012;81:97-117. doi: 10.1146/annurev-biochem-052610-091920 PMID: 22404632.
23. Fotouhi O, Adel Fahmideh M, Kjellman M, Sulaiman L, Hoog A, Zedenius J, et al. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: An in vivo and in vitro study. Epigenetics: official journal of the DNA Methylation Society. 2014;9(7). PMID: 24762809.
24. Sidhu S, Martin E, Gicquel C, Melki J, Clark SJ, Campbell P, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2005;31(5):549-54. doi: 10.1016/j.ejso.2005.01.013 PMID: 15922892.
25. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Molecular cell. 2008;29(3):392-400. doi: 10.1016/j.molcel. 2007.12.025 PMID: 18280244.
26. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Molecular cell. 2007;25(5):725-38. doi: 10.1016/j.molcel.2007.02.007 PMID: 17349958.
27. Clayton PE, Hanson D, Magee L, Murray PG, Saunders E, Abu-Amero SN, et al. Exploring the spectrum of 3-M syndrome, a primordial short stature disorder of disrupted ubiquitination. Clinical endocrinology. 2012;77(3):335-42. doi: 10.1111/j.1365-2265.2012.04428.x PMID: 22624670.
28. Tokumoto M, Fujiwara Y, Shimada A, Hasegawa T, Seko Y, Nagase H, et al. Cadmium toxicity is caused by accumulation of p53 through the down-regulation of Ube2d family genes in vitro and in vivo. The Journal of toxicological sciences. 2011;36(2):191-200. PMID: 21467746.
29. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(2):328-36. doi: 10.1158/1078-0432. CCR-10-2006 PMID: 21088256.
30. Meani N, Pezzimenti F, Deflorian G, Mione M, Alcalay M. The tumor suppressor PRDM5 regulates Wnt signaling at early stages of zebrafish development. PloS one. 2009;4(1):e4273. doi: 10.1371/journal. pone.0004273 PMID: 19169355; PubMed Central PMCID: PMC2627919.
31. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/beta-catenin signaling and is frequently silenced in multiple tumors. PloS one. 2011;6(11):e27346. doi: 10.1371/journal.pone.0027346 PMID: 22087297; PubMed Central PMCID: PMC3210799.
32. Suwa T, Chen M, Hawks CL, Hornsby PJ. Zonal expression of dickkopf-3 and components of the Wnt signalling pathways in the human adrenal cortex. The Journal of endocrinology. 2003;178(1):149-58. PMID: 12844346.
33. Leal LF, Mermejo LM, Ramalho LZ, Martinelli CE Jr., Yunes JA, Seidinger AL, et al. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors. The Journal of clinical endocrinology and metabolism. 2011;96(10):3106-14. doi: 10.1210/jc.2011-0363 PMID: 21849527.
34. Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochimica et biophysica acta. 2012;1825(1):18-28. doi: 10.1016/j.bbcan. 2011.09.003 PMID: 21982838.
35. Bickeboller M, Tagscherer KE, Kloor M, Jansen L, Chang-Claude J, Brenner H, et al. Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival. Oncogene. 2015;34(9):1150-9. doi: 10.1038/onc.2014.40 PMID: 24662837.
36. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Molecular cancer. 2008;7:62. doi: 10.1186/1476-4598-7-62 PMID: 18616821; PubMed Central PMCID: PMC2483990.